Cardiac Adverse Events and Remdesivir in COVID-19 Patients: Discovery Trial Safety Analysis

2024-05-02 10:48:20

(1) Terzić V (1,2), Miantezila Basilua J (1,2), Billard N (3), de Gastines L (1,2), Belhadi D (3,6), Fougerou-Leurent C (4), Peiffer- Smadja N (5,6), Mercier N (1,2), Delmas C (7), Ferrane A (7), Dechanet A (3), Poissy J (8), Espérou H (7), Ader F (9 ) ), Hites M (10), Andrejak C (11), Greil R (12), Paiva JA (13), Staub T (14), Tacconelli E (15), Burdet C (3), Costagliola D (16) , Mentré F (3,6), Yazdanpanah Y (3,5,17), Diallo A (1,2) and the study group Discovery. Cardiac adverse events and remdesivir in hospitalized patients with Coronavirus Disease 2019 (COVID-19): A post hoc safety analysis of the randomized Discovery trial.

Clin Infect Dis 2024 Mar 29:ciae170.

Clinical Trial Safety and Public Health, ANRS|Emerging Infectious Diseases, Paris, France

Clinical Research Safety Department, INSERM, Paris, France

Department of Epidemiology, Biostatistics and Clinical Research, Hospital Bichat, APHP, Paris, France

Pharmacology Unit, Rennes University Hospital; CIC Inserm 1414, Rennes University Hospital, Rennes, France

Department of Infectious Diseases, Bichat – Claude-Bernard Hospital, APHP, Paris, France

Paris Cité University, IAME, INSERM, Paris, France

Clinical Research Center, INSERM, Paris, France

University of Lille, Inserm U1285, Lille University Hospital, Intensive Care Unit, CNRS, UMR 8576 – UGSF – Structural and Functional Glycobiology Unit, Lille, France

Department of Infectious and Tropical Diseases, Hospices Civils de Lyon, F-69004, Lyon, and International Center for Research in Infectiology (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon , F-69007, Lyon, France

Department of Infectious Diseases, Brussels University Hospital (HUB)-Erasme, Brussels, Belgium

Pulmonology Unit, University Hospital Amiens-Picardie, UR 4294 AGIR, Université Picardie Jules Verne, Amiens, France

IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunological Studies (SCRI-CCCIT); Cancer Cluster Salzburg; Austrian Group for Medical Tumor Therapy (AGMT), Salzburg, Austria

Intensive Care Medicine Service, Centro Hospitalar Universitário São João, Porto, Portugal

Center Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, Luxembourg

Infectious diseases, Dept. Diagnostics and Public Health, University of Verona, Verona, Italy

Sorbonne University, INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Paris, France

ANRS Emerging Infectious Diseases, Paris, France

(2) Gottlieb RL and Kalil AC. True detection of COVID-19 disease burden versus speculated antiviral cardiovascular risk requires a control group. Clin Infect Dis 2024 Mar 29:ciae172.

(3) https://cordis.europa.eu/project/id/101015736

Funded by Europe (The EU’s Horizon 2020 research and innovation program under grant agreement no. 101015736), Discovery is now research axis 1 in the EU-RESPONSE project (European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases, which brings together 22 partners (clinics, hospitals, universities, etc.) from 13 countries in the EU, Norway, Switzerland, Luxembourg and Turkey.

(4) Ader F, et al. Final results of the Discovery study of remdesivir for patients hospitalized with COVID-19. Lancet Infect Dis 2022;22(6):764-765.

(5) Gottlieb RL, et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022;386(4):305-315.

(6) Amstutz A, et al. Effects of remdesivir in patients hospitalized with COVID-19: a systematic review and individual patient data meta-analysis of randomized controlled trials. Lancet Respir Med 2023; 11(5):453-464.

1714647901
#Discovery #Remdesivir #expose #hospitalized #patients #Covid19 #increased #risk #cardiac #effects